The Insight Partners Latest Research on Report “Acute Lung Injury Market Forecast to 2028″ Includes COVID-19 Impact and Global Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others) and Geography
“Acute Lung Injury Market is expected to reach US$ 741.98 million by 2028 from US$ 539.61 million in 2021; it is estimated to register a CAGR of 4.7% from 2021 to 2028. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the market growth. Factors such as increasing prevalence of respiratory diseases and rising geriatric population are the key factors driving the market growth. However, the high cost of therapies hinders market growth.
Download PDF Sample Copy at: https://www.theinsightpartners.com/sample/TIPRE00015798/
Based on therapy, the acute lung injury market is segmented into mechanical ventilation, fluid management, pharmacotherapy, and adjunctive procedures. In 2021, the mechanical ventilation segment accounted for the largest market share in the global acute lung injury market. The segment’s growth is attributed to the fact that mechanical ventilation in acute lung injury (ALI) aims to maintain oxygen while avoiding its toxicity and complications associated with the ventilation.
Based on end user, the acute lung injury market is segmented into hospitals, ambulatory surgery centers, and others. The hospitals segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR of 4.9% of the market during the forecast period.
The growth of the market is attributed to increasing prevalence of respiratory diseases, and rising geriatric population drive the market growth. However, high cost of therapies hampers the market growth.
Inquire about Discount: https://www.theinsightpartners.com/discount/TIPRE00015798/
Leading Players are:
- GlaxoSmithKline plc.
- Stemedica Cell Technologies, Inc
- APEPTICO Forschung und Entwicklung GmbH
- Windtree Therapeutics, Inc.
- ReAlta Life Sciences, Inc.
- Apeiron Biologics AG
- Qx Therapeutics, Inc.
- Asklepion Pharmaceuticals, LLC
For instance, in March 2021, Qx Therapeutics Inc. announced that the US Food and Drug Administration (FDA) cleared investigational new drug application (IND) to investigate its lead drug product, QXT-101, for a Phase 2 clinical trial for its safety and efficacy in hospitalized patients with severe or critical COVID-19. QXT-101 is a first-in-class treatment for patients who suffer from acute lung injury (ALI). Thus, continuous efforts and investments by the market players to address the rising demands by boosting the production and sales of their products in the domestic and international markets are driving the acute lung injury market.
Buy Report at: https://www.theinsightpartners.com/buy/TIPRE00015798/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi